Propranolol Hydrochloride Tablets, USP
- Manufacturer
- Dispensing Solutions, Inc. | PSS World Medical, Inc.
- Effective date
- 2012-02-16
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 20:14:28
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Rx Only
DESCRIPTION
hydrochloride(Propranolol is a synthetic beta-adrenergic receptor blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,(±)-. It’s molecular and structural formulae are:
Propranolol hydrochloride is a stable, white, crystalline solid which is readily soluble in water and in ethanol. Its molecular weight is 295.80.
Propranolol hydrochloride tablets, USP are available as 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg tablets for oral administration.
The inactive ingredients contained in propranolol hydrochloride tablets, USP are: lactose monohydrate, corn starch, sodium starch glycolate, magnesium stearate, and povidone. In addition, propranolol hydrochloride tablets, USP 10 mg, 40 mg and 80 mg contain and C yellow No.6 Aluminium Lake and Color D and C Yellow No. 10; propranolol hydrochloride tablets, USP 20 mg and 40mg contain FD and C Blue No.1 and propranolol hydrochloride tablets, USP 60 mg contain D and C Red No. 30 Lake.
CONTRAINDICATIONS
Propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first degree block; 3) bronchial asthma; and 4) in patients with known hypersensitivity to propranolol hydrochloride.
ADVERSE REACTIONS
The following adverse events were observed and have been reported in patients using propranolol.
Cardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.
Central Nervous System: Lightheadedness, mental depression manifested by insomnia, lassitude, weakness, fatigue; catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate-release formulations, fatigue, lethargy, and vivid dreams appear dose-related.
Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.
Allergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis; erythematous rash, fever combined with aching and sore throat; laryngospasm, and respiratory distress.
Respiratory: Bronchospasm.
Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.
Autoimmune: Systemic lupus erythematosus (SLE).
Skin and mucous membranes: Stevens-Johnson Syndrome, toxic epidermal necrolysis, dry eyes, exfoliative dermatitis, erythema multiforme, urticaria, alopecia, SLE-like reactions, and psoriasiform rashes. Oculomucocutaneous syndrome involving the skin, serous membranes and conjunctivae reported for a beta-blocker (practolol) have not been associated with propranolol.
Genitourinary: Male impotence; Peyronie’s disease.
OVERDOSAGE
Propranolol is not significantly dialyzable. In the event of overdosage or exaggerated response, the following measures should be employed:
General: If ingestion is or may have been recent, evacuate gastric contents, taking care to prevent pulmonary aspiration.
Supportive Therapy: Hypotension and bradycardia have been reported following propranolol overdose and should be treated appropriately. Glucagon can exert potent inotropic and chronotropic effects and may be particularly useful for the treatment of hypotension or depressed myocardial function after a propranolol overdose. Glucagon should be administered as 50-150 mcg/kg intravenously followed by continuous drip of 1-5 mg/hour for positive chronotropic effect. Isoproterenol, dopamine or phosphodiesterase inhibitors may also be useful. Epinephrine, however, may provoke uncontrolled hypertension. Bradycardia can be treated with atropine or isoproterenol. Serious bradycardia may require temporary cardiac pacing.
The electrocardiogram, pulse, blood pressure, neurobehavioral status and intake and output balance must be monitored. Isoproterenol and aminophylline may be used for bronchospasm.
HOW SUPPLIED
Propranolol hydrochloride tablets, USP are supplied as follows:
10mg: Each tablet is an orange colored, round, biconvex tablet, embossed with "P" and "10" on either side of the breakline on one side and plain on the other side.
Each 10 mg tablet contains 10 mg propranolol hydrochloride USP and is supplied in the following packages sizes:
Bottles of 30 tablets NDC 23155-110-03
Bottles of 60 tablets NDC 23155-110-06
Bottles of 100 tablets NDC 23155-110-01
Bottles of 500 tablets NDC 23155-110-05
Bottles of 1000 tablets NDC 23155-110-10
20mg: Each tablet is a blue colored, round, biconvex tablet, embossed with "P" and "20" on either side of the breakline on one side and plain on the other side.
Each 20 mg tablet contains 20 mg of propranolol hydrochloride USP and is supplied in the following package sizes:
Bottles of 30 tablets NDC 23155-111-03
Bottles of 60 tablets NDC 23155-111-06
Bottles of 100 tablets NDC 23155-111-01
Bottles of 500 tablets NDC 23155-111-05
Bottles of 1000 tablets NDC 23155-111-10
40mg: Each tablet is a green colored, round, biconvex tablet, embossed with "P" and "40"on either side of the breakline on one side and plain on the other side.
Each 40 mg tablet contains 40 mg of propranolol hydrochloride USP and is supplied in the following package sizes:
Bottles of 30 tablets NDC 23155-112-03
Bottles of 60 tablets NDC 23155-112-06
Bottles of 100 tablets NDC 23155-112-01
Bottles of 500 tablets NDC 23155-112-05
Bottles of 1000 tablets NDC 23155-112-10
60mg: Each tablet is a pink colored, round, biconvex tablet, embossed with "P" and "60" on either side of the breakline on one side and plain on the other side.
Each 60 mg tablet contains 60 mg of propranolol hydrochloride USP and is supplied in the following package sizes:
Bottles of 30 tablets NDC 23155-113-03
Bottles of 60 tablets NDC 23155-113-06
Bottles of 100 tablets NDC 23155-113-01
Bottles of 500 tablets NDC 23155-113-05
Bottles of 1000 tablets NDC 23155-113-10
80mg: Each tablet is a yellow colored, round, biconvex tablet, embossed with "P" and "80" on either side of the breakline on one side and plain on the other side.
Each 80 mg tablet contains 80 mg of propranolol hydrochloride USP and is supplied in the following package sizes:
Bottles of 30 tablets NDC 23155-114-03
Bottles of 60 tablets NDC 23155-114-06
Bottles of 100 tablets NDC 23155-114-01
Bottles of 500 tablets NDC 23155-114-05
Bottles of 1000 tablets NDC 23155-114-10
Storage: Store at 20°-25°C (68-(°77(°F); excursions permitted to 15°-30(°C (59(°-86(°F) [see USP Controlled Room Temperature]
Protect from light.
Dispense in a well closed, light-resistant container as defined in USP.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
SPL UNCLASSIFIED SECTION
Manufactured for:
Heritage Pharmaceuticals Inc.
Edison, NJ 08837
1.866.901.DRUG (3784)
Manufactured by:
Ipca Laboratories Limited
48, Kandivli Ind. Estate,
Mumbai 400 067, India.
Iss. 0109
PRINCIPAL DISPLAY PANEL
NDC 68258-6010-XX
NDC 68258-6010-03
NDC 68258-6010-09
DailyMed RxNorm Mappings#
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| PROPRANOLOL Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| ba1babb5-1c2a-d9a8-0fd7-8f90d4f768cf | Product name | 2 | 20200609 |
| a5696e6c-a559-4d6b-bb53-f324106f317c | Product name | 1 | 20140718 |
| 0f446d3d-c9e6-1844-b8e8-a836dc35e0de | Product name | 1 | 20140508 |
| 33a4b7b4-a3c1-3f95-a202-01166dd77c44 | Product name | 1 | 20140508 |
| 60519d27-227d-404a-38bc-37524c8b386b | Product name | 1 | 20140508 |
| d5f30598-8f94-b083-f161-65d67f2ae12a | Product name | 1 | 20140508 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68258-6010-3 | 2019-11-13 | C162847 | 48780-1 | 97449f38-cbfc-f6ea-e053-dbdaa90aa703 | Propranolol Hydrochloride Tablets, USP |
| 68258-6010-9 | 2019-11-13 | C162847 | 48780-1 | 97449f38-cbfc-f6ea-e053-dbdaa90aa703 | Propranolol Hydrochloride Tablets, USP |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68258-6010-3 | Propranolol Hydrochloride | 30 in 1 BOTTLE | TABLET | 30 | 1 | |
| 68258-6010-9 | Propranolol Hydrochloride | 90 in 1 BOTTLE | TABLET | 90 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68258-6010 | PROPRANOLOL HYDROCHLORIDE TABLET [DISPENSING SOLUTIONS, INC.] | 1 | Legacy NDC, 2 package rows | 20120313_7bcb754b-df3e-4a8d-98aa-8be1ed3e8ec3.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 23155-111-01 | EA - Each | 23155-111 | c22f7406-6ff6-498c-b22d-2770cdbdffab | 1 | 2012-07-24 |
| 23155-111-10 | EA - Each | 23155-111 | e2dd72e7-8a0c-4205-a490-188e369607c7 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| PROPRANOLOL HYDROCHLORIDE | ACTIVE INGREDIENT | F8A3652H1V | 1 | |
| PROPRANOLOL | ACTIVE MOIETY | 9Y8NXQ24VQ | 1 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| POVIDONE | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO | INACTIVE INGREDIENT | 5856J3G2A2 | 1 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 |
Products#
Every source-derived product name is available through these pages.
- Propranolol Hydrochloride
- PROPRANOLOL
- FD&C BLUE NO. 1
- LACTOSE MONOHYDRATE
- MAGNESIUM STEARATE
- POVIDONE
- SODIUM STARCH GLYCOLATE TYPE A POTATO
- STARCH, CORN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68258-6010 | 68258-6010-3, 68258-6010-9 |
| 23155-111 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| PROPRANOLOL HYDROCHLORIDE | F8A3652H1V | ACTIM |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| POVIDONE | FZ989GH94E | IACT |
| SODIUM STARCH GLYCOLATE TYPE A POTATO | 5856J3G2A2 | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POVIDONE | POVIDONE | FZ989GH94E | SOLUTION / ORAL | 3000 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | PASTILLE / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, FILM COATED / ORAL | 0.16 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOAP / TOPICAL | 0.01 %w/w | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 750 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, DELAYED RELEASE / ORAL | 1060 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | POWDER / RESPIRATORY (INHALATION) | 25 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, EXTENDED RELEASE / ORAL | 2575 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, COATED / ORAL | 256 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | POWDER, FOR SUSPENSION / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | POWDER, FOR SUSPENSION / ORAL | 34 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING / ORAL | 100 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, DELAYED RELEASE / ORAL | 2 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, EXTENDED RELEASE / ORAL | 101 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE, FOR SUSPENSION / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, EXTENDED RELEASE / ORAL | 1 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / SUBLINGUAL | 409 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | DOUCHE / VAGINAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / SUBLINGUAL | 0.03 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION, EXTENDED RELEASE / ORAL | 113 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 690 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 9.5 %w/v | ||
| POVIDONE | POVIDONE | FZ989GH94E | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 350 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE / ORAL | 5785 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / DENTAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 214 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 32 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | CAPSULE, EXTENDED RELEASE / ORAL | 56 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 214 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| POVIDONE | POVIDONE | FZ989GH94E | TROCHE / ORAL | 30 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 0.01 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CREAM / VAGINAL | 586 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, DELAYED RELEASE / ORAL | 713 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 107 mg |
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A078955-001 | PROPRANOLOL HYDROCHLORIDE | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | |
| A078955-002 | PROPRANOLOL HYDROCHLORIDE | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | |
| A078955-003 | PROPRANOLOL HYDROCHLORIDE | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | |
| A078955-004 | PROPRANOLOL HYDROCHLORIDE | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | |
| A078955-005 | PROPRANOLOL HYDROCHLORIDE | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A078955-001 | AB |
| A078955-002 | AB |
| A078955-003 | AB |
| A078955-004 | AB |
| A078955-005 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-001 | PROPRANOLOL HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2008-06-02 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-002 | PROPRANOLOL HYDROCHLORIDE | 20MG | TABLET / ORAL | AB | 2008-06-02 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-003 | PROPRANOLOL HYDROCHLORIDE | 40MG | TABLET / ORAL | AB | 2008-06-02 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-004 | PROPRANOLOL HYDROCHLORIDE | 60MG | TABLET / ORAL | AB | 2008-06-02 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-005 | PROPRANOLOL HYDROCHLORIDE | 80MG | TABLET / ORAL | AB | 2008-06-02 | 03ed91905a0d… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A078955-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A078955-002 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A078955-003 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A078955-004 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A078955-005 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A078955-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A078955-002 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A078955-003 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A078955-004 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A078955-005 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-002 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-003 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-004 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A078955-005 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-002 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-003 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-004 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A078955-005 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-002 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-003 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-004 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A078955-005 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-001 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-002 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-003 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-004 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A078955-005 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-001 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-002 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-003 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-004 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A078955-005 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-001 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-002 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-003 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-004 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A078955-005 | AB | 1 | 03ed91905a0d… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 69a5de8c-248f-4613-b495-ea310d23fdfd | 7bcb754b-df3e-4a8d-98aa-8be1ed3e8ec3 | 2012-02-16 | Adverse reactions | 69a5de8c-248f-4613-b495-ea310d23fdfd 7bcb754b-df3e-4a8d-98aa-8be1ed3e8ec3 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.


